A domestic biosimilar taking an unstoppable run in the global market

The Celltrion’s rheumatoid arthritis treatment, ‘Remsima,’ has continued to accelerate in the global market. The number of exports from the early year to June has already exceeded the one of the last whole year.

Remsima is the world’s first antibody biosimilar developed by Celltrion having the Johnson & Johnson’s(J&J) rheumatoid arthritis treatment, ‘Remicade,’ as the comparator; it was approv...